FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Healthcare & Life Sciences Enterprise Capital Monitor – Europe 06/2023”. The Monitor is a month-to-month printed overview of enterprise capital developments within the European Life Sciences sector.
As of the tip of June 2023 we establish the next present VC developments in Europe:
- In 2023, total Life Sciences funding has reached EUR 4,865m
- Biotech acquired 47% of the entire funding quantity (+2% in comparison with the earlier month)
- Oncology dominates as the highest indication in Biotechnology
- Ellipses Pharma (United Kingdom) has the best transaction quantity of EUR 126m in June, adopted by Beacon Therapeutics (United Kingdom) EUR 111m and Corwave (France) EUR 61m
- Revival Healthcare Capital (United States) dominates the Prime 5 Buyers (by deal quantity), adopted by European Innovation Council Fund (Belgium) and Gilde Healthcare Companions (Netherlands)
- Prime 5 Offers exceed EUR 120m every, the biggest transaction amounted to EUR 683m in YgEia3 (United Kingdom)
To entry the total report, please click on right here.
By Mathias Klozenbücher, Johannes Hyperlink and Marco Buonafede-Bennardo.